Phosphodiesterase-4: Selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 326-333

  Giembycz, Mark A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cyclic adenosine monophosphate; Dual specificity phosphodiesterase inhibitors; Phosphodiesterase 1; Phosphodiesterase 3; Phosphodiesterase 7

Indexed keywords

CILOMILAST; CYCLIC AMP; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII; ROFLUMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTERITIS; BLEEDING; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; ENZYME SPECIFICITY; HUMAN; INFLAMMATION; LUNG FUNCTION; NAUSEA; POLYARTERITIS; VASCULAR NECROSIS; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 27644589238     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200504-041SR     Document Type: Conference Paper

References (10)

1. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-370.
2. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-270.
3. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investis Drugs 2001;10:1361-1379.
4. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002;57:48-64.
5. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-982.
6. Ruben Z, Deslex P, Nash G, Redmond NI, Poncet M, Dodd DC. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 1989;17:145-152.
7. Bishop SP. Animal models of vasculitis. Toxicol Pathol 1989;17:109-117.
8. Pulmonary-Allergy Drug Products Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. SB 207499 (Ariflo, Cilomilast), GlaxoSmithKline: NewDrugs Application (21-573). Available from: www. fda.gov/ohrms/dockets/ac/03/ transcripts/3976T1.doc (accessed August 11, 2005).
9. Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 2004;32:295-308.